Literature DB >> 18634017

Erythropoietin improves functional and histological recovery of traumatized skeletal muscle tissue.

Robert Rotter1, Marija Menshykova, Tobias Winkler, Georg Matziolis, Ioannis Stratos, Matthias Schoen, Thomas Bittorf, Thomas Mittlmeier, Brigitte Vollmar.   

Abstract

Apart from its hematopoietic effect, erythropoietin (EPO) is known as pleiotropic cytokine with anti-inflammatory and anti-apoptotic properties. Here, we evaluated for the first time the EPO-dependent regeneration capacity in an in vivo rat model of skeletal muscle trauma. A myoblast cell line was used to study the effect of EPO on serum deprivation-induced cell apoptosis in vitro. A crush injury was performed to the left soleus muscle in 80 rats treated with either EPO or saline. Muscle recovery was assessed by analysis of contraction capacities. Intravital microscopy, BrdU/laminin double immunohistochemistry and cleaved caspase-3 immunohistochemistry of muscle tissue on days 1, 7, 14, and 42 posttrauma served for assessment of local microcirculation, tissue integrity, and cell proliferation. Serum deprivation-induced myoblast apoptosis of 23.9 +/- 1.5% was reduced by EPO to 17.2 +/- 0.8%. Contraction force analysis in the EPO-treated animals revealed significantly improved muscle strength with 10-20% higher values of twitch and tetanic forces over the 42-day observation period. EPO-treated muscle tissue displayed improved functional capillary density as well as reduced leukocytic response and consecutively macromolecular leakage over day 14. Concomitantly, muscle histology showed significantly increased numbers of BrdU-positive satellite cells and interstitial cells as well as slightly lower counts of cleaved caspase-3-positive interstitial cells. EPO results in faster and better regeneration of skeletal muscle tissue after severe trauma and goes along with improved microcirculation. Thus, EPO, a compound established as clinically safe, may represent a promising therapeutic option to optimize the posttraumatic course of muscle tissue healing.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18634017     DOI: 10.1002/jor.20692

Source DB:  PubMed          Journal:  J Orthop Res        ISSN: 0736-0266            Impact factor:   3.494


  24 in total

1.  Three weeks of erythropoietin treatment hampers skeletal muscle mitochondrial biogenesis in rats.

Authors:  Vladimir E Martinez-Bello; Fabian Sanchis-Gomar; Marco Romagnoli; Frederic Derbre; Mari Carmen Gomez-Cabrera; Jose Viña
Journal:  J Physiol Biochem       Date:  2012-05-25       Impact factor: 4.158

2.  Skeletal muscle intrinsic functional properties are preserved in a model of erythropoietin deficient mice exposed to hypoxia.

Authors:  Luciana Hagström; Francis Canon; Onnik Agbulut; Dominique Marchant; Bernard Serrurier; Jean-Paul Richalet; Michèle Beaudry; Xavier Bigard; Thierry Launay
Journal:  Pflugers Arch       Date:  2010-01-30       Impact factor: 3.657

3.  Applications of In Vivo Functional Testing of the Rat Tibialis Anterior for Evaluating Tissue Engineered Skeletal Muscle Repair.

Authors:  Ellen L Mintz; Juliana A Passipieri; Daniel Y Lovell; George J Christ
Journal:  J Vis Exp       Date:  2016-10-07       Impact factor: 1.355

Review 4.  Novel avenues of drug discovery and biomarkers for diabetes mellitus.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  J Clin Pharmacol       Date:  2010-03-10       Impact factor: 3.126

5.  Diabetes mellitus: channeling care through cellular discovery.

Authors:  Kenneth Maiese; Yan Chen Shang; Zhao Zhong Chong; Jinling Hou
Journal:  Curr Neurovasc Res       Date:  2010-02       Impact factor: 1.990

6.  Endogenous erythropoietin signaling facilitates skeletal muscle repair and recovery following pharmacologically induced damage.

Authors:  Yi Jia; Norio Suzuki; Masayuki Yamamoto; Max Gassmann; Constance Tom Noguchi
Journal:  FASEB J       Date:  2012-04-09       Impact factor: 5.191

7.  Erythropoietin receptor (EpoR) agonism is used to treat a wide range of disease.

Authors:  Fabian Sanchis-Gomar; Carme Perez-Quilis; Giuseppe Lippi
Journal:  Mol Med       Date:  2013-04-30       Impact factor: 6.354

8.  Epo is relevant neither for microvascular formation nor for the new formation and maintenance of mice skeletal muscle fibres in both normoxia and hypoxia.

Authors:  Luciana Hagström; Onnik Agbulut; Raja El-Hasnaoui-Saadani; Dominique Marchant; Fabrice Favret; Jean-Paul Richalet; Michèle Beaudry; Thierry Launay
Journal:  J Biomed Biotechnol       Date:  2010-04-14

9.  Erythropoietin administration partially prevents adipose tissue loss in experimental cancer cachexia models.

Authors:  Fabio Penna; Silvia Busquets; Miriam Toledo; Fabrizio Pin; David Massa; Francisco J López-Soriano; Paola Costelli; Josep M Argilés
Journal:  J Lipid Res       Date:  2013-08-21       Impact factor: 5.922

10.  Blunting effect of hypoxia on the proliferation and differentiation of human primary and rat L6 myoblasts is not counteracted by Epo.

Authors:  T Launay; L Hagström; S Lottin-Divoux; D Marchant; P Quidu; F Favret; A Duvallet; T Darribère; J P Richalet; M Beaudry
Journal:  Cell Prolif       Date:  2010-02       Impact factor: 6.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.